ARQULE - Positive Data in HCC is an Add-On!
Positive PhII data of Tivantinib (formerly ARQ-197, c-MET inhibitor) in 2nd line HepatoCellular Carcinoma (HCC) expands the opportunity as there are no FDA approved drugs available for this indication. Tivantinib showed statistically significant improvement of 56% in time-to-progression (TTP) in the intent-to-treat (ITT previously treated HCC pts) with a hazard ratio (HR) of 0.64 (p-value = 0.04). Moreover, failure of BMY’s Brivanib (PhIII, HCC 2nd line) to fulfill this unmet need raises expectations and the efficacy bar for Tivantinib. We remain positive on an approval of Tivantinib in its lead indication – NSCLC by 2014 and have assigned peak sales of… For more details, please read our report released on 19th January, 2012 on ArQule titled “Positive Data in HCC is an Add-On!”
COMPANIES MENTIONED
ARQULE
ARQULE
